M&T Bank Corp Increases Position in Eli Lilly and Company $LLY

Key Points

• M&T Bank raised its stake in Eli Lilly by 2.7% in Q4, buying 6,540 shares to hold 250,692 shares worth about $269.4 million, roughly 0.9% of its portfolio and the firm's 25th-largest position.
• Eli Lilly reported a strong Q1 with $19.8B revenue and $8.55 non‑GAAP EPS, and raised FY2026 guidance to $82–85B revenue and EPS of 35.50–37.00, fueling analyst upgrades and the stock rally.
• Management cites early traction for oral GLP‑1 Foundayo (>20,000 patients) and a potential regulatory tailwind from the FDA limiting compounding, though valuation, competitive and pricing risks persist; institutional investors own about 82.5% of the stock.

M&T Bank Corp raised its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 250,692 shares of the company's stock after buying an additional 6,540 shares during the period. Eli Lilly and Company comprises approximately 0.9% of M&T Bank Corp's investment portfolio, making the stock its 25th biggest position. M&T Bank Corp's holdings in Eli Lilly and Company were worth $269,414,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. 10Elms LLP lifted its holdings in Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company's stock worth $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. boosted its holdings in Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company's stock valued at $1,587,000 after purchasing an additional 10 shares during the last quarter. Tanager Wealth Management LLP boosted its holdings in Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company's stock valued at $424,000 after purchasing an additional 10 shares during the last quarter. Morey & Quinn Wealth Partners LLC grew its position in shares of Eli Lilly and Company by 1.5% during the 4th quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company's stock valued at $710,000 after acquiring an additional 10 shares during the period. Finally, Wealthspan Partners LLC grew its position in shares of Eli Lilly and Company by 0.5% during the 4th quarter. Wealthspan Partners LLC now owns 2,110 shares of the company's stock valued at $2,268,000 after acquiring an additional 10 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 results and guidance boost: Lilly reported roughly $19.8B revenue and $8.55 non‑GAAP EPS (well above consensus), raised 2026 revenue guidance to $82–85B and lifted EPS guidance to $35.50–37 — a primary driver of the rally. Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth
• Positive Sentiment: Foundayo (oral GLP‑1) early traction: Foundayo — the first oral GLP‑1 with no food/water timing restrictions — has seen early prescriptions (management cites >20,000 patients), supporting longer‑term market share and convenience advantages versus rivals. Lilly's Double-Beat Widens the GLP-1 Gap—And a New Pill Could Make It Permanent
• Positive Sentiment: Regulatory tailwind for pricing/protection: The FDA proposed excluding key GLP‑1 active ingredients from the compounding bulk list — a move that would limit cheaper mass compounding and help protect branded volumes/pricing. US FDA proposes excluding weight-loss drugs from compounding list
• Positive Sentiment: Street upgrades and higher price targets: Major banks raised price targets and reiterated buy/overweight ratings after the results and guidance, supporting momentum from institutional analysts. Cantor Fitzgerald raises PT
• Neutral Sentiment: Novo’s oral rollout increases scrutiny: Novo Nordisk is expanding its oral GLP‑1 presence (rebranded Rybelsus/Ozempic pills across many pharmacies), a development investors will watch but which hasn’t flipped the narrative away from Lilly yet. Novo Launches Ozempic Pills Across 70,000 US Pharmacies
• Neutral Sentiment: Valuation and long‑term upside debate: Several analyses highlight a tension between Lilly’s strong top‑line growth and a stretched valuation after multi‑year gains; some see material upside if GLP‑1 momentum persists, others caution about multiple compression risk. Eli Lilly Stock’s Path To 30% Upside
• Negative Sentiment: Competitive and pricing pressure risks remain: PBM/insurer negotiation, faster ramps from rivals and longer‑term generic/compounding threats could pressure realized prices and margin expansion — a risk highlighted in market commentary despite the quarter’s beat. Fast Money panel on Novo vs Lilly
• Negative Sentiment: Regulatory / stakeholder friction: Hospital groups have pushed back on certain Lilly data/340B requests, which could create policy or reimbursement friction to monitor. AHA urges HHS to block Lilly 340B data demands

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $965.19 on Monday. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The stock has a market cap of $911.93 billion, a P/E ratio of 34.29, a price-to-earnings-growth ratio of 1.13 and a beta of 0.48. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a fifty day simple moving average of $947.05 and a 200-day simple moving average of $987.36.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share for the quarter, beating analysts' consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm had revenue of $19.80 billion during the quarter, compared to analysts' expectations of $17.82 billion. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company's quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Equities analysts expect that Eli Lilly and Company will post 33.79 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Weiss Ratings reaffirmed a "buy (b)" rating on shares of Eli Lilly and Company in a research note on Friday, March 27th. Truist Financial reaffirmed a "buy" rating on shares of Eli Lilly and Company in a research report on Monday, February 23rd. Zacks Research lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 30th. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $1,260.00 to $1,283.00 and gave the company a "buy" rating in a report on Friday. Finally, Sanford C. Bernstein reiterated an "outperform" rating on shares of Eli Lilly and Company in a report on Tuesday, March 10th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of "Moderate Buy" and a consensus price target of $1,212.96.

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.